{
  "schemaVersion": "orion-company-promise-record-v1",
  "ticker": "CRBP",
  "company": "Corbus Pharmaceuticals",
  "url": "https://www.orionbiotechai.com/company/CRBP",
  "generatedFrom": "founder-checked batch, as of 2026-10-12",
  "records": [
    {
      "chainId": "A20-CRBP-701-1L-COMBO",
      "program": "CRB-701 + pembrolizumab / first-line OPSCC · 1L combination clinical data",
      "eventLabel": "Clinical results disclosure",
      "status": "Window open",
      "statusDefinition": "https://www.orionbiotechai.com/orion-methodology.html#promise-status-window-open",
      "firstStated": {
        "statement": "Anticipate reporting CRB-701 + Keytruda® combination data in first-line (1L) settings in OPSCC patients in Q1 2027",
        "window": "Q1 2027",
        "documentType": "SEC Exhibit 99.1",
        "date": "2026-08-06",
        "dateBasis": "filing_date",
        "url": "https://www.sec.gov/Archives/edgar/data/1595097/000119312526336864/crbp-ex99_1.htm"
      },
      "restatements": [
        {
          "kind": "Statement retained",
          "statement": "Anticipate reporting CRB-701 + Keytruda® combination data in first-line (1L) settings in OPSCC patients in Q1 2027",
          "window": "Q1 2027",
          "documentType": "Company press release",
          "date": "2026-08-06",
          "dateBasis": "company_release",
          "url": "https://ir.corbuspharma.com/news-events/press-releases/detail/475/corbus-pharmaceuticals-reports-q2-2026-financial-results-and-provides-a-corporate-update"
        },
        {
          "kind": "Statement retained",
          "statement": "Report CRB-701 + pembrolizumab data in 1L — Q1 2027",
          "window": "Q1 2027",
          "documentType": "SEC Exhibit 99.2",
          "date": "2026-09-14",
          "dateBasis": "filing_date",
          "url": "https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-389829/crbp-ex99_2.htm"
        }
      ],
      "disclosure": null,
      "additionalDisclosures": [],
      "scopeNotes": [
        "The initial entry means the earliest wording located within the sources checked; an exhaustive history is not asserted.",
        "Company timing wording is retained. A newer corporate release about another program does not establish a results announcement for this trial."
      ],
      "scopeSources": [],
      "companyReleases": [
        {
          "date": "2026-08-06",
          "url": "https://ir.corbuspharma.com/news-events/press-releases/detail/475/corbus-pharmaceuticals-reports-q2-2026-financial-results-and-provides-a-corporate-update"
        },
        {
          "date": "2026-09-29",
          "url": "https://ir.corbuspharma.com/news-events/press-releases/detail/479/corbus-pharmaceuticals-announces-first-patient-dosed-in-tempo-1-registrational-study-of-crb-701-in-patients-with-2l-oropharyngeal-cancer"
        }
      ],
      "companySourceChecks": [
        {
          "url": "https://ir.corbuspharma.com/news-events/press-releases",
          "checkedDate": "2026-10-10",
          "label": "Company press release listing"
        }
      ],
      "secCheckedThrough": "2026-09-14",
      "secScope": "8-K and Ex-99.1 Jan–Aug 2026, 10-Q Mar 31, Ex-99.2 Sep 2026 checked for CRB-701 1L combination timing.",
      "companyPrCheckedDate": "2026-10-10",
      "companyPrScope": "Press releases page checked on Oct 10; CRB-913 obesity items are a separate program.",
      "founderCheckedDate": "2026-10-10",
      "rowsShown": 1,
      "rowsTotal": 1,
      "citation": "Corbus Pharmaceuticals (CRBP) — CRB-701 + pembrolizumab / first-line OPSCC · 1L combination clinical data: “Q1 2027” (SEC Exhibit 99.1 2026-08-06); statement retained “Q1 2027” (2026-08-06); statement retained “Q1 2027” (2026-09-14). Status Window open, checked 2026-10-10. Sources: https://www.sec.gov/Archives/edgar/data/1595097/000119312526336864/crbp-ex99_1.htm | https://ir.corbuspharma.com/news-events/press-releases/detail/475/corbus-pharmaceuticals-reports-q2-2026-financial-results-and-provides-a-corporate-update | https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-389829/crbp-ex99_2.htm",
      "corrections": []
    }
  ]
}